Evidence map›Paper›PMID 38891058›Full record

ArticleCells2024

Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes.

Viktor Sincic, Ken F Arlenhold, Sarah Richtmann, Henrik Lilljebjörn, Pontus Eriksson, Gottfrid Sjödahl, Mats Wokander, Karin Hägerbrand, Peter Ellmark, Thoas Fioretos and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Viktor SincicDepartment of Immunotechnology, Lund University, 223 81 Lund, Sweden.
Ken F ArlenholdDepartment of Immunotechnology, Lund University, 223 81 Lund, Sweden.
Sarah RichtmannDepartment of Immunotechnology, Lund University, 223 81 Lund, Sweden.ORCID 0000-0001-7368-8297
Henrik LilljebjörnDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, 221 84 Lund, Sweden.
Pontus ErikssonDivision of Oncology, Department of Clinical Sciences Lund, Lund University, 221 84 Lund, Sweden.
Gottfrid SjödahlDepartment of Translational Medicine, Lund University, 205 02 Malmö, Sweden.ORCID 0000-0002-7869-0473
Mats WokanderDepartment of Urology, Skåne University Hospital, 205 02 Malmö, Sweden.
Karin HägerbrandAlligator Bioscience AB, Medicon Village, 223 63 Lund, Sweden.
Peter EllmarkDepartment of Immunotechnology, Lund University, 223 81 Lund, Sweden.ORCID 0000-0002-6687-1250
Thoas FioretosDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, 221 84 Lund, Sweden.
Carl A K BorrebaeckDepartment of Immunotechnology, Lund University, 223 81 Lund, Sweden.
Fredrik LiedbergDepartment of Translational Medicine, Lund University, 205 02 Malmö, Sweden.
Kristina LundbergDepartment of Immunotechnology, Lund University, 223 81 Lund, Sweden.ORCID 0000-0002-1421-8081

Funding

Cancera Foundation NAEuropean Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie 847583Faculty of Engineering (LTH) NAFoundation of Urological Research (Ove and Carin Carlsson bladder cancer donation) NAGösta Jönsson Research Foundation NAGunnar Nilsson Cancer Foundation NAHillevi Fries Research Foundation NAISREC Foundation NALund Medical Faculty (ALF) NAMats Paulsson Foundation NAPer-Erik och Ulla Schybergs stiftelse/Royal Physiographic Society of Lund NASkåne University Hospital Research Funds NAStefan Paulsson Foundation NASwedish Cancer Society CAN 2023/2807Swedish Research Council 2021-00859The Cancer Research Fund at Malmö General Hospital NAThe Hjelm Family Foundation for Medical research NA
6 · The paper itself

Abstract

Bladder cancer is a heterogenous disease, and molecular subtyping is a promising method to capture this variability. Currently, the immune compartment in relation to subtypes is poorly characterized. Here, we analyzed the immune compartment in bladder tumors and normal bladder urothelium with a focus on T cell subpopulations using flow cytometry and RNA sequencing. The results were investigated in relation to tumor invasiveness (NMIBC/MIBC) and molecular subtypes according to the Lund Taxonomy system. Whereas the NMIBC/MIBC differed in the overall immune infiltration only, the molecular subtypes differed both in terms of immune infiltration and immune compartment compositions. The Basal/Squamous (Ba/Sq) and genomically unstable (GU) tumors displayed increased immune infiltration compared to urothelial-like (Uro) tumors. Additionally, the GU tumors had a higher proportion of regulatory T cells within the immune compartment compared to Uro tumors. Furthermore, sequencing showed higher levels of exhaustion in CD8

Indexed as

Urinary Bladder NeoplasmsAgedCD8-Positive T-LymphocytesFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedT-LymphocytesTumor MicroenvironmentUrotheliumbladder cancerexhaustionimmunotherapymolecular subtypesT cell population

Identifiers

PMID38891058
PMCPMC11171717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.